Evaluating the Effect of a Synbiotic Formulation on Alzheimer’s Disease Pathology in Drosophila

0 views • 1:24 min • August 7th, 2025

Take a transgenic Drosophila.

The brain of the Drosophila expresses the human amyloid peptide protein or APP and a cleaving enzyme.

The enzyme cleaves APP, enabling the formation of beta-amyloid plaque, which leads to

Alzheimer's disease or AD pathology in Drosophila.

Feed the Drosophila AD model a diet containing a synbiotic formulation.

The formulation contains a combination of three bioactive probiotic bacteria and a prebiotic.

Inside the fly's gut, the prebiotic supports the growth and survival of the probiotics.

Probiotics produce metabolites and mediators that communicate with the host brain through a pathway known as the gut-brain axis.

Within the host cell, these byproducts can activate a transcription factor that regulates multiple

biological processes, thereby influencing AD symptoms through the GBA.

Use various assays, such as survivability, motility, and beta-amyloid accumulation, to evaluate the effect of the synbiotic formulation on AD pathology.

View the full transcript and gain access to thousands of scientific videos

Sign In

Explore More Videos

Drosophila Alzheimer Model